New Study Published in JAMA Supports Neurotez, Inc. Plans for the Development of Leptin as a Therapy for AD
12/17/2009 9:53:13 AM
BRIDGEWATER, N.J.--(BUSINESS WIRE)--This week’s issue of the Journal of the American Medical Association (Dec 16) features a report on a long-term, prospective study of elderly, dementia-free individuals led by researchers from Boston University School of Medicine and the Framingham Heart Study focusing on the association between the protein hormone Leptin and the risk of developing Alzheimer’s disease (AD). Specifically, people with higher baseline circulating Leptin levels were found to have a significantly reduced incidence of AD and dementia. Individuals in the lowest quartile of gender-specific Leptin levels had an absolute AD risk of 25%, while persons in the highest quartile had only a 6% risk over a 12-year follow-up period.